Tag: BARDA
Vaxxas secures $2M grant from BARDA to develop needle-free mRNA vaccines
Vaxxas, a clinical-stage biotechnology company specializing in high-density microarray patch (HD-MAP) vaccine delivery, has been awarded a $2 million (AUD 3.2 million) grant as a Concept Stage winner in the United States Biomedical Advanced Research and Development Authority’s (BARDA) $50 million Patch Forward Prize.
SAB Biotherapeutics awarded $57.5 to manufacture its therapeutic candidate for COVID-19
Clinical stage biopharma company SAB Biotherapeutics has been awarded $57.5 million from BARDA and the US Department of Defence for the manufacturing of SAB-185,...
Featured Article
“New Starts Here”: AGHA launches national platform for gift and homewares
Australia’s peak organisation for the gift and homewares sector, the Australian Gift & Homewares Association (AGHA), has revealed plans for a major expansion in 2026, introducing Gifted Melbourne 2026 to complement the long-established AGHA Sydney Gift Fair.
